Study of AZD0754 in Participants With Metastatic Prostate Cancer
NCT06267729
This study is recruiting at 9 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Metastatic Prostate Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 to 130 years
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- AstraZeneca
- Last updated on ClinicalTrials.gov
- February 23, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Research Site · Duarte, CA
Florida · 1
- Research Site · Tampa, FL
Georgia · 1
- Research Site · Atlanta, GA
Missouri · 1
- Research Site · St Louis, MO
New Jersey · 1
- Research Site · Hackensack, NJ
New York · 2
- Research Site · New York, NY
- Research Site · New York, NY
Pennsylvania · 1
- Research Site · Philadelphia, PA
Texas · 1
- Research Site · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.